{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:42:56Z","timestamp":1792096976475,"version":"4.4.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.pnpbp.2010.07.018","type":"journal-article","created":{"date-parts":[[2010,7,24]],"date-time":"2010-07-24T11:00:12Z","timestamp":1279969212000},"page":"373-379","source":"Crossref","is-referenced-by-count":94,"title":["Novel insights for the treatment of Alzheimer's disease"],"prefix":"10.1016","volume":"35","author":[{"given":"Alexander","family":"Kurz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Perneczky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2010.07.018_bb0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuron.2008.06.018","article-title":"Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hdroxy quinoline analogs is associated with decreased interstitial Abeta","volume":"59","author":"Adlard","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2174\/156720507781788882","article-title":"Alzhemed: a potential treatment for Alzheimer's disease","volume":"4","author":"Aisen","year":"2008","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1468-1331.2006.01222.x","article-title":"A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolsysin in patients with mild to moderate Alzheimer's disease","volume":"13","author":"Alvarez","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0020","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00401-009-0536-x","article-title":"Synaptic degeneration in Alzheimer's disease","volume":"118","author":"Arendt","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0025","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1749-6632.2003.tb07541.x","article-title":"Mitochondria as a targe for neurotoxins and neuroprotective agents","volume":"993","author":"Bachurin","year":"2003","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0030","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12031-008-9139-6","article-title":"The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats","volume":"37","author":"Bar-Am","year":"2009","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0035","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hpothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0040","first-page":"110","article-title":"Six-month randomized, placebo-conrolled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease","volume":"28","author":"Baum","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0045","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.expneurol.2008.03.004","article-title":"Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons","volume":"211","author":"Bishop","year":"2008","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0050","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cbpa.2009.04.619","article-title":"Alzheimer's disease: new approaches to drug discovery","volume":"13","author":"Bolognesi","year":"2009","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1124\/pr.108.000562","article-title":"Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection","volume":"61","author":"Buckingham","year":"2009","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0166-2236(03)00067-5","article-title":"The metallobiology of Alzheimer's disease","volume":"26","author":"Bush","year":"2003","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0065","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2353\/ajpath.2007.061178","article-title":"Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles","volume":"170","author":"Caccamo","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0070","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00401-006-0071-y","article-title":"Neuropathology of Alzheimer disease: pathognomonic but not pathogenic","volume":"111","author":"Castellani","year":"2006","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0075","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1196\/annals.1427.027","article-title":"Mitochondrial approaches for neuroprotection","volume":"1147","author":"Chaturvedi","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/JAD-1998-1102","article-title":"Delivery of nerve growth factor to the brain via the olfactory pathway","volume":"1","author":"Chen","year":"1998","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0085","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/01.wnl.0000295996.54210.69","article-title":"Disease-modifying therapies for Alzheimer's disease. Challenges to early intervention","volume":"69","author":"Cummings","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0090","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/S1092852900027024","article-title":"Integrating symptomatic and disease-modifying treatments","volume":"13","author":"Cummings","year":"2008","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0095","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jalz.2008.12.003","article-title":"Defining and labeling disease-modifying treatments for Alzheimer's disease","volume":"5","author":"Cummings","year":"2009","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0100","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.neurobiolaging.2007.02.029","article-title":"Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Abeta oligomers","volume":"29","author":"De Felice","year":"2008","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0105","doi-asserted-by":"crossref","first-page":"475","DOI":"10.5483\/BMBRep.2009.42.8.475","article-title":"Insulin resistance and Alzheimer's disease","volume":"42","author":"De la Monte","year":"2009","journal-title":"BMB Rep"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0110","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/187152709787601867","article-title":"Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease","volume":"8","author":"Deane","year":"2009","journal-title":"CNS Neurol Dis Drug Targets"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0115","doi-asserted-by":"crossref","first-page":"T168","DOI":"10.1016\/j.jalz.2008.05.442","article-title":"EHT-0202: a neuroprotective and procognitive alpha-secretase stimulator targeted towards Alzheimer disease therapy","volume":"4","author":"Desire","year":"2008","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0120","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.jalz.2007.10.010","article-title":"We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development","volume":"4","author":"Doody","year":"2008","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","article-title":"Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study","volume":"372","author":"Doody","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12603-009-0045-6","article-title":"What have we learned from the xaliproden Sanofi-Aventis trials","volume":"13","author":"Douillet","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0135","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0140","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/0269881107066855","article-title":"Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)","volume":"21","author":"Dunbar","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0145","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0197-4580(97)00047-X","article-title":"Prevalence, incidence and duration of Braak's stages in the general population: can we know?","volume":"18","author":"Duyckaerts","year":"1997","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0150","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/bjp.2008.147","article-title":"The histamine H3 receptor: an attractive target fr the treatment of cognitive disorders","volume":"154","author":"Ebenshade","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0155","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00702-006-0575-6","article-title":"The significance of neuroinflammation in understanding Alzheimer's disease","volume":"113","author":"Eikelenboom","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0160","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000017069","article-title":"Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease","volume":"9","author":"Eriksdotter-J\u00f6nhagen","year":"1998","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0165","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1172\/JCI18162","article-title":"NSAIDs and enatniomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo","volume":"112","author":"Eriksen","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0170","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000122962","article-title":"Treatment options in Alzheimer's disease: maximizing benefit, managing expectations","volume":"25","author":"Farlow","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0175","doi-asserted-by":"crossref","first-page":"13623","DOI":"10.1016\/S0021-9258(17)36875-8","article-title":"Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative","volume":"269","author":"Gabuzda","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0180","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","article-title":"Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study","volume":"13","author":"Gauthier","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000197881","article-title":"Pathological substrates of cognitive decline in Alzheimer's disease","volume":"24","author":"Giannakopoulos","year":"2009","journal-title":"Front Neurol Neurosci"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0190","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bbadis.2009.08.010","article-title":"Cause and consequence: Mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative disease","volume":"1802","author":"Gibson","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0195","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1471-4159.2006.04211.x","article-title":"Disease modifying therapy for AD?","volume":"99","author":"Golde","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0200","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbrc.2009.01.041","article-title":"Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells","volume":"380","author":"Greco","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0205","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer's disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA."},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0210","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0278-5846(88)90102-9","article-title":"Glutamate transmission and toicity in Alzheimer's disease","volume":"12","author":"Greenamyre","year":"1988","journal-title":"Prog Neuro-Psych Biol Psych."},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0215","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2165\/00002512-200623120-00003","article-title":"Effects of cholinesterase inhibitors on behavioural disturbances in Alzheimer's disease. A systematic review","volume":"23","author":"Grimmer","year":"2006","journal-title":"Drugs Aging"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0220","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0024-3205(03)00320-5","article-title":"A multicenter, randomized, placebo controlled, multiple-dose, safety and pahrmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients","volume":"73","author":"Grundman","year":"2003","journal-title":"Life Sci"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0225","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S1474-4422(06)70526-9","article-title":"Adiposity indices and dementia","volume":"5","author":"Gustafson","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0230","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.08m04606","article-title":"Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study","volume":"70","author":"Hampel","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0235","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","article-title":"Tau phosphorylation: the therapeutic challenge for neurodegenerative disease","volume":"15","author":"Hanger","year":"2009","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0240","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1471-4159.2009.06181.x","article-title":"The amyloid hypothesis for Alzheimer's disease: a critical reappraisal","volume":"110","author":"Hardy","year":"2009","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0245","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1460-9568.2009.07052.x","article-title":"Small molecule beta-amyloid inhibitors that stabilize protofibrillar structures in vitor improve cognition and pathology in a mouse model of Alzheimer's disease","volume":"31","author":"Hawkes","year":"2010","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0250","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1517\/14656560903044982","article-title":"Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease","volume":"10","author":"Henley","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0255","doi-asserted-by":"crossref","first-page":"T166","DOI":"10.1016\/j.jalz.2008.05.437","article-title":"Efficacy and tolerability of SB-742457, a novel 5HT6 receptor antagonis, in subjects with mild-to-moderate Alzheimer's disease (AD)","volume":"4","author":"Hind","year":"2008","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0260","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of A beta 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0265","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","article-title":"The GSK3 hypothesis of Alzheimer's disease","volume":"104","author":"Hooper","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0270","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/anie.200802808","article-title":"Alzheimer's disease: From pathology to therapeutic approaches","volume":"48","author":"Jakob-Roetne","year":"2009","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0275","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1468-1331.2009.02737.x","article-title":"Nutrition and Alzheimer's disease: pre-clinical concepts","volume":"16","author":"Kamphuis","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0280","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jns.2009.02.352","article-title":"Therapeutic potential of statins in Alzheimer's disease","volume":"283","author":"Kandiah","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0285","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0006-8993(98)00138-3","article-title":"Stimulation of alpha-4-beta-2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity","volume":"792","author":"Kihara","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0290","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","article-title":"Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial","volume":"7","author":"Lannfelt","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0295","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1001\/jama.2009.1836","article-title":"Association of plasma leptin levels with incident Alzheimer's disease and MRI measures of brain aging","volume":"302","author":"Lieb","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0300","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1212\/01.wnl.0000260269.93245.d2","article-title":"Naproxen and celecoxib do no prevent AD in early results from a randomized controlled trial","volume":"68","author":"Lyketsos","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0305","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000051227","article-title":"Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease","volume":"11","author":"Maelicke","year":"2000","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0310","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/00002512-200421070-00001","article-title":"Treatment strategies in Alzheimer's disease with a focus on early pharmacological interventions","volume":"21","author":"Marksteiner","year":"2004","journal-title":"Drugs Aging"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0315","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.brainres.2008.11.057","article-title":"Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A","volume":"1252","author":"Martin","year":"2009","journal-title":"Brain Res"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0320","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1124\/jpet.107.130526","article-title":"A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease","volume":"325","author":"Matsuoka","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0325","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.pharmthera.2005.05.001","article-title":"5-HT6 receptors: a novel target for cognitive enhancement","volume":"108","author":"Mitchell","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0330","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/(SICI)1097-0258(20000615\/30)19:11\/12<1401::AID-SIM432>3.0.CO;2-X","article-title":"Longitudinal studies of cognitive, functionsl and behavioural change in patients with Alz heimer's disease","volume":"19","author":"Mohs","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0335","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nm.1912","article-title":"Neuroprotecive effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease","volume":"15","author":"Nagahara","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0340","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amylodi-beta peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/REVNEURO.2009.20.1.1","article-title":"Is Alzheimer's disease a result of presynaptic failure? Synaptic dysfunctions induced by oligomeric beta-amyloid","volume":"20","author":"Nimmrich","year":"2009","journal-title":"Rev Neurosci"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0350","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after a beta 42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0355","first-page":"1015","article-title":"Functional mimetics of neurotrophins and their receptors","volume":"12","author":"Peleshok","year":"2006","journal-title":"Biochim Soc Trans"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0360","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2165\/11203320-000000000-00000","article-title":"A review of its use in dementia","volume":"26","author":"Plosker","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0365","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.pharmthera.2007.03.005","article-title":"Advances in small molecules promoting neurotrophic function","volume":"115","author":"Price","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0370","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimer's disease","volume":"362","author":"Querfurth","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0375","doi-asserted-by":"crossref","first-page":"P207","DOI":"10.1016\/j.jalz.2009.04.117","article-title":"Effects of 12months of treatment with the PPARgamma agonist rosiglitazone on brain glucose metabolism in Alzheimer's disease: A 18F-FDG PET study","volume":"5","author":"Rabiner","year":"2009","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0380","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1371\/journal.pmed.0040338","article-title":"Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials","volume":"4","author":"Raschetti","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0385","doi-asserted-by":"crossref","first-page":"18177","DOI":"10.1074\/jbc.M709715200","article-title":"Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases","volume":"283","author":"Reynolds","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0390","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/1567205053585882","article-title":"A potential role of the curry spice curcumin in Alzheimer's disease","volume":"2","author":"Ringman","year":"2005","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0395","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","article-title":"Efficacy of rosiglitazone in a genetically defined population with mild-to moderate Alzheimer's disease","volume":"6","author":"Risner","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0400","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","article-title":"Metal-protein attenuation with iodochorhydroxyquin (Clioquinol) targeting A beta amyloid deposition and toxicity in Alzheimer disease. A pilot phase 2 clinical trial","volume":"60","author":"Ritchie","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0405","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.amjopharm.2009.06.003","article-title":"Drug development for Alzheimer's disease: where are we now and where are we headed?","volume":"7","author":"Sabbagh","year":"2009","journal-title":"Am J Geriatr Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0410","first-page":"80","article-title":"Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea","volume":"11","author":"Sabbagh","year":"2010","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0415","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2009.10.003","article-title":"Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial","volume":"6","author":"Scheltens","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0425","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00702-006-0579-2","article-title":"The significance of the cholinergic system in the brain during aging and in Alzheimer's disase","volume":"113","author":"Schliebs","year":"2006","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0430","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/sj.bjp.0707471","article-title":"Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation","volume":"152","author":"Selenica","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0435","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/14789450.5.2.207","article-title":"Biochemistry of Tau in Alzheimer's disease and related neurological disorders","volume":"5","author":"Sergeant","year":"2008","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0440","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JAD-2008-15202","article-title":"Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies","volume":"15","author":"Sigurdsson","year":"2008","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0445","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1196\/annals.1427.003","article-title":"Mitochondria-targeted antioxidants in the treatment of disease","volume":"1147","author":"Smith","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0450","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm0798-822","article-title":"Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy","volume":"4","author":"Soto","year":"1998","journal-title":"Nature Med"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0455","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.tins.2008.11.007","article-title":"Tau pathophysiology in neurodegeneration: a tangled issue","volume":"32","author":"Spires-Jones","year":"2009","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0460","article-title":"Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease","author":"Srikanth","year":"2009","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0465","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00401-009-0517-0","article-title":"Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis","volume":"118","author":"Sultana","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0470","first-page":"347","article-title":"Pathogenesis of Alzheimer's disease","volume":"2","author":"Swerdlow","year":"2007","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0475","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.expneurol.2009.01.011","article-title":"The Alzheimer's disease mitochondrial cascade hypothesis: an update","volume":"218","author":"Swerdlow","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0480","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1471-4159.2007.05072.x","article-title":"Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein","volume":"104","author":"Tamagno","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0485","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainresrev.2008.07.007","article-title":"New insights into brain BDFN function in normal aging and alzheimer disease","volume":"59","author":"Tapia-Arancibia","year":"2008","journal-title":"Brain Res Rev"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0490","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3233\/JAD-2009-1021","article-title":"Leptin: a novel therapeutic strategy for Alzheimer's disease","volume":"16","author":"Tezapsidis","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0495","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2174\/138161210790170094","article-title":"Cognitive improvement by activation of alpha 7 nicotinic acetylcholine receptors: from animal models to human pathophysiology","volume":"16","author":"Thomsen","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0500","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm1239","article-title":"A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease","volume":"11","author":"Tuszynski","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0505","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/157015909787602823","article-title":"Oxidative stress and neurodegenerative disease: a review of upstream and downstream antioxidant therapeutic options","volume":"7","author":"Uttara","year":"2009","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0510","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1017\/S0317167100027694","article-title":"Cognitive enhancing agents: current status in the treatment of Alzheimer's disease","volume":"15","author":"Waters","year":"1988","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0515","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-2202-9-S2-S1","article-title":"Small molecule activators of the Trk receptors for neuroprotection","volume":"9","author":"Webster","year":"2008","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0520","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00702-007-0630-y","article-title":"Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease","volume":"114","author":"Wei","year":"2007","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0525","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/156720508784533286","article-title":"Functional consequences of locus coeruleus degeneration in Alzheimer's disease","volume":"5","author":"Weinshenker","year":"2008","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0530","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00401-009-0498-z","article-title":"Microvasculature changes and cerebrl amyloid angiopathy in Alzheimer's disease and their potential impact on therapy","volume":"118","author":"Weller","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0535","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","article-title":"Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial","volume":"7","author":"Wilcock","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0540","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1126\/science.1132341","article-title":"Control of peripheral nerve myelination by the beta-secretase BACE1","volume":"314","author":"Willem","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0545","doi-asserted-by":"crossref","first-page":"T167","DOI":"10.1016\/j.jalz.2008.05.438","article-title":"Taui aggregation inhibitor (TAI) therapy with Rember TM arrests disease progression in mild and moderate Alzheimer's disease over 50weeks","volume":"4","author":"Wischik","year":"2008","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0550","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(08)70170-4","article-title":"Amyloid-beta immunisation for Alzheimer's disease","volume":"7","author":"Wisniewski","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0555","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2202-9-S2-S5","article-title":"Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors","volume":"9","author":"Wisniewski","year":"2008","journal-title":"BMD Neuroscience"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0560","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1073\/pnas.0406361102","article-title":"Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0565","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2147\/ciia.2006.1.2.143","article-title":"Economic considerations in the management of Alzheimer's disease","volume":"1","author":"Zhu","year":"2006","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.pnpbp.2010.07.018_bb0570","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrneurol.2009.54","article-title":"Brain-derived neuroptrophic factor in neurodegenerative disease","volume":"5","author":"Zuccato","year":"2009","journal-title":"Nat Rev Neurol"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584610002812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584610002812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T17:59:02Z","timestamp":1711648742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584610002812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0278584610002812"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2010.07.018","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}